Rotenone, Paraquat, and Parkinson’s Disease by Tanner, Caroline M. et al.
866  v o l u m e  119 | n u m b e r 6 | June 2011  •  Environmental Health Perspectives
Research
Mitochondrial dysfunction and oxidative stress 
have long been implicated as pathophysiologic 
mechanisms underlying Parkinson’s disease 
(PD) (Betarbet et al. 2000; Di Monte et al. 
2002). Genetic forms of PD associated with 
mutations in the alpha-synuclein, PARKIN, 
PINK1, or DJ-1 genes may involve these 
mechanisms (Henchcliffe and Beal 2008). In 
experimental models, the pesticides paraquat, 
which causes oxidative stress, and rotenone, 
which inhibits mitochondrial complex I, both 
induce loss of nigral dopaminergic neurons 
and behavioral changes associated with human 
PD (Henchcliffe and Beal 2008). Yet despite 
decades of laboratory study, neither pesticide 
has been definitively associated with PD in 
humans. Previous studies have reported asso-
ciations with paraquat, but results are incon-
sistent and, in general, studies included few 
exposed cases; evidence concerning rotenone 
is sparse (Table 1). To assess the relevance 
of experimental results to human PD, we 
investigated the association of PD with use 
of pesticides linked to complex I inhibition 
or oxidative stress in a population with well-
characterized pesticide exposure.
The Farming and Movement Evaluation 
study (FAME) is a case–control study nested 
in the Agricultural Health Study (AHS), a pro-
spective study including 84,740 private pesti-
cide applicators (mostly farmers), recruited in 
1993–1997 in Iowa and North Carolina, and 
their spouses (Alavanja et al. 1996). Pesticide 
use is reported reliably by these applicators 
(Blair et al. 2002; Hoppin et al. 2002). We 
previously reported that self-reported PD was 
associated with increasing lifetime days of 
use of any pesticide, but no specific pesticide 
could be definitely implicated (Kamel et al. 
2007). In this study, we assessed lifelong use 
of pesticides with toxicant mechanisms rel-
evant to PD. Because 15–25% of self-reported 
PD diagnoses in community populations may 
be incorrect (Tolosa et al. 2006), we based 
diagnoses on in-person examination and con-
sensus of two experts, minimizing diagnostic 
misclassification and enabling analyses of clin-
ical features. We report here results from our 
investigation of pesticides previously associ-
ated with mitochondrial complex I inhibition 
(termed “complex I inhibitors”) or oxidative 
stress (termed “oxidative stressors”).
Methods
Case and control identification. From among 
AHS cohort members who were private pes-
ticide applicators (mostly farmers) and their 
spouses, we identified persons suspected to 
have PD based on diagnoses from self-reports 
or state mortality files. We selected potential 
controls by stratified random sampling of 
all AHS participants. Cohort members who 
were ultimately diagnosed with PD or parkin-
sonism, dead, cognitively impaired, or seriously 
ill were not eligible to be controls. Controls 
were frequency-matched to cases by age (< 40, 
40–49, 50–59, 60–64, 65–69, ≥ 70 years), sex, 
and state (Iowa or North Carolina) at a ratio of 
approximately three controls per case.
Living suspect cases and all potential 
controls were assessed during home visits. 
Movement disorder specialist neurologists 
(subsequently called “neurologists”) assessed 
all cases and 5% of controls. Neurologist-
trained technicians assessed the remaining 
controls. The in-person assessment included 
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Ba c k g r o u n d: Mitochondrial dysfunction and oxidative stress are pathophysiologic mechanisms 
implicated in experimental models and genetic forms of Parkinson’s disease (PD). Certain pesticides 
may affect these mechanisms, but no pesticide has been definitively associated with PD in humans.
oBjectives: Our goal was to determine whether pesticides that cause mitochondrial dysfunction or 
oxidative stress are associated with PD or clinical features of parkinsonism in humans.
Me t h o d s : We assessed lifetime use of pesticides selected by mechanism in a case–control study 
nested in the Agricultural Health Study (AHS). PD was diagnosed by movement disorders special-
ists. Controls were a stratified random sample of all AHS participants frequency-matched to cases 
by age, sex, and state at approximately three controls:one case.
re s u l t s: In 110 PD cases and 358 controls, PD was associated with use of a group of pesticides 
that inhibit mitochondrial complex I [odds ratio (OR) = 1.7; 95% confidence interval (CI), 1.0–2.8] 
including rotenone (OR = 2.5; 95% CI, 1.3–4.7) and with use of a group of pesticides that cause 
oxidative stress (OR = 2.0; 95% CI, 1.2–3.6), including paraquat (OR = 2.5; 95% CI, 1.4–4.7).
co n c l u s i o n s: PD was positively associated with two groups of pesticides defined by mechanisms 
implicated experimentally—those that impair mitochondrial function and those that increase oxida-
tive stress—supporting a role for these mechanisms in PD pathophysiology. 
key w o r d s : aging, agricultural epidemiology, environmental epidemiology, epidemiology, fun-
gicides, herbicides, insecticides, persistent organic pollutants, pesticides. Environ Health Perspect 
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factors used to diagnose PD and to distin-
guish PD from other disorders, including a 
standardized medical and neurological history, 
the Cognitive Abilities Screening Instrument 
(Teng et al. 1994), a scripted, standardized 
videotaped assessment of parkinsonism, a 
handwriting sample, medications, and the 
University of Pennsylvania brief smell identifi-
cation test (Sensonics, Inc., Haddon Heights, 
NJ, USA) (Doty et al. 1996). Assessments by 
neurologists also included a standardized neu-
rological examination, orthostatic hypoten-
sion assessment, the Unified Parkinson’s 
Disease Rating Scale (Fahn et al. 1987), and 
the Tremor Rating Scale (Fahn et al. 1993). 
Technician-assessed controls with signs sug-
gesting parkinsonism were subsequently 
assessed by a neurologist.
Diagnosis was determined by agreement of 
two neurologists (C.M.T. and either G.W.R., 
C.M., A.C., or M.K.) after independent review 
of all available diagnostic information (medi-
cal records, in-person examination records, 
and videotaped examination) for all suspect 
cases and when PD was suspected in a control. 
Established criteria for PD and related dis-
orders were used (Bain et al. 2000; Elble 2000; 
Gelb et al. 1999; Gilman et al. 1999; Hughes 
et al. 1992; Langston et al. 1992; Litvan et al. 
1996; McKeith et al. 1996).
FAME was approved by institutional 
review boards for the Parkinson’s Institute, 
National Institutes of Health, Social and 
Scientific Systems, Inc. (Durham, NC, USA), 
the University of Iowa (Iowa field station), and 
Battelle, Inc. (North Carolina field station). All 
participants provided written informed consent.
Exposure assessment. We used computer-
assisted telephone interviews to obtain detailed 
information on pesticide use from 14 years 
of age onward for 31 selected pesticides 
[Supplemental Material, Table 1 (doi:10.1289/
ehp.1002839)] as well as covariate information 
including lifelong smoking and family history 
of PD. For subjects who were unable to com-
plete interviews, we used proxy informants. 
Although all controls were living and compe-
tent when enrolled, some later became unable 
to participate and a proxy informant was used. 
We considered only pesticide use occurring 
before a reference date (cases: age at PD diag-
nosis; controls: median age of PD diagnosis for 
cases within the corresponding age-, sex-, and 
state-specific stratum). For each pesticide, we 
determined ever use (used one or more times) 
and lifetime days of use (determined for each 
farm job by multiplying years of use by average 
days of use per year, and then summing across 
jobs). Self-reported pesticide use falling outside 
U.S. Environmental Protection Agency (EPA) 
approval dates was not included. For cigarette 
smoking, we classified individuals who smoked 
> 100 cigarettes before their reference date as 
exposed (Grant et al. 2004). Family history 
of PD was positive if the subject reported PD 
in any first-degree relative. We dichotomized 
educational level as ≤ 12 years and > 12 years.
Statistical analyses. We compared par-
ticipant characteristics using Fisher’s exact 
test or Pearson’s chi-square statistic for cat-
egorical data and the Wilcoxon rank-sum test 
for continuous data. For pesticides reported 
by ≥ 10 subjects, we evaluated associations 
between pesticide use and PD using uncon-
ditional logistic regression to derive odds 
ratios (ORs) and 95% confidence inter-
vals (CIs) [Supplemental Material, Table 2 
(doi:10.1289/ehp.1002839)]. To control 
potential confounding, we included refer-
ence age (tertiles 40–57, 58–65, 66–87 years), 
sex, state, and cigarette smoking (ever/never) 
Table 1. Relationship of PD to paraquat or rotenone exposure in human populations.
Study Design
Method of assessing 
pesticide use
No. enrolled  
(cases, controls) Finding
OR (95% CI) 
or p-value Exposed n
Paraquat
Sanchez-Ramos 
et al. 1987
Case report Medical history 1 case Symptoms “comparable to PD” in a 32-year-
old farmer after 15 years of paraquat use
NA 1 case
Hertzman et al. 1990 Case–control Specific question 
re: paraquat use
57 cases Association with PD  p = 0.0*a 4 cases
122 controls 0 controls
Semchuk et al. 1992 Case–control General questions 
re: pesticide use
130 cases One case with early-onset PD (< age 40 years) NA 1 case
260 cases reported using paraquat (ages 26–31 years)
Hertzman et al. 1994 Case–control Specific question 
re: paraquat use
127 cases 1.11 (0.32–3.87) 6 cases
245 controls No association with PD 5 controls
1.25 (0.34–4.63) 6 cases
4 controls
Liou et al. 1997 Case–control Open-ended question 
re: pesticide use
120 cases No association with PD 3.22 (2.41–4.31) 31 cases
240 controls 22 controls
Firestone et al. 2005 Case–control Checklistb 250 cases Association with PD 1.67 (0.22–12.76) 2 cases
388 controls 2 controls
Kamel et al. 2007 Case–control Specific question 
re: paraquat use
83 prevalent cases Association with PD in prevalent cases  1.8 (1.0–3.4) 14 prevalent
79,557 controls 11,266 controls
78 incident cases No association with PD in incident cases  1.0 (0.5–1.9) 11 incident
55,931 controls 7,382 controls
Tanner et al. 2009 Case–control Specific question 
re: occupational 
paraquat use
519 cases  Association with PD 2.80 (0.81–9.72) 9 cases
511 controls 4 controls
Firestone et al. 2010 Case–control Checklistc 404 incident cases Added subjects to 2005 interim population 0.9 (0.14–5.43) 2 cases
526 controls No association with PD in reanalysis 3 controls
Rotenone
Kamel et al. 2007 Case–control Specific question 
re: rotenone use in 
a supplementary 
questionnaire 
83 prevalent cases Association of PD with ever use 1.7 (0.6–4.7) 4 prevalent
79,557 controls 671 controls
78 incident cases Could not determine  1 incident
55,931 controls 565 controls
Tanner et al. 2009 Case–control Specific question 
re: occupational 
rotenone use
519 cases No association with PD 0.82 (0.05–13.34) 1 case
511 controls 1 control
Dhillon et al. 2008 Case–control General question 
re: “organic pesticides”
100 cases Greater use of “organic pesticides such as 
rotenone” in PD patients
10.0 (2.9–34.3) 27 cases
84 controls 3 controls
NA, not analyzed.
aFour PD patients and no controls reported paraquat contact; OR could not be calculated; bOccupational pesticide exposures were identified from a checklist of common chemical agents 
and home-based pesticide exposures from a checklist of commercial brand name products. cSubjects reported exposures to various industrial toxicants identified from a checklist.Tanner et al.
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in all models. We also examined whether 
adjusting for overall pesticide use or educa-
tional level changed point estimates (± 15%) 
for individual pesticides. To adjust for over-
all pesticide use, we categorized individuals 
who used pesticides on < 25 lifetime days as 
unexposed and others as exposed, using data 
reported at enrollment in the AHS (data from 
AHS data release version P1REL0506 and 
AHSREL0612; unpublished data).  
We performed analyses for pesticide expo-
sure groups classified by mechanism as com-
plex I inhibitors or oxidative stressors, based on 
literature review (Degli Esposti 1998; Krieger 
2001; Uversky et al. 2001) and information in 
public databases [Agency for Toxic Substances 
and Disease Registry (ATSDR) 2002; 
Extension Toxicology Network (EXTOXNET) 
2002; National Center for Biotechnology 
Information 2002]. Because men were the pri-
mary users of pesticides, we repeated analyses 
of ever use and duration of use restricted to 
men. For each pesticide reported by > 30 men 
[Supplemental Material, Table 3 (doi:10.1289/
ehp.1002839)], we assessed the effect of expo-
sure duration by separately comparing less use 
(at or below the median number of cumula-
tive days of use) or more use (use above the 
median) with never use of that pesticide.
We repeated primary analyses in sub-
groups defined by race/ethnicity (non-His-
panic whites, others), state, family history of 
PD, cigarette use, and respondent status (self-
reported vs. proxy-reported pesticide data) 
and, in cases, PD duration. We performed 
analyses for rotenone and paraquat use trun-
cated 5, 10, and 15 years before the index 
date to evaluate whether the association of PD 
with pesticide use was influenced by behav-
ioral changes caused by undiagnosed disease. 
We also assessed the combination of paraquat 
plus any dithiocarbamate (ferbam, mancozeb, 
maneb, metam sodium, vegedex, zineb, ziram), 
because previous studies  reported an asso-
ciation of PD with the combination of para-
quat and the dithiocarbamate maneb (Costello 
et al. 2009; Thiruchelvam et al. 2000). We 
also repeated the primary analysis after includ-
ing cases of atypical parkinsonism in our case 
group. For cases, we compared clinical features 
in persons who did or did not use paraquat or 
oxidative stressors as a group, or rotenone or 
complex I inhibitors as a group.
We used SAS version 9.1.3 (SAS Institute 
Inc., Cary, NC, USA) and SPSS version 12.0 
(SPSS Inc., Chicago, IL, USA) for statistical 
analyses. We used α ≤ 0.05 as a criterion for 
statistical significance.
Results
We identified 170 suspect cases and 644 
potential controls and screened 156 (92%) and 
542 (84%) of these, respectively (Figure 1). 
We conducted study evaluations in 137 (88%) 
of eligible suspect cases (including 4 initially 
indentified as potential controls who self-re-
ported PD at screening) and 383 (71%) of 
eligible potential controls. Final diagnoses in 
suspect cases were PD (115), essential tremor/
other tremor disorder (12), no neurologic 
diagnosis (5), dystonia (2), multiple system 
atrophy (2), and atypical parkinsonism not 
fulfilling any diagnostic criterion (1), the lat-
ter three cases subsequently termed “atypical 
parkinsonism.”
The analyses reported here include 110 PD 
cases and 358 controls who provided complete 
information on pesticide use and application 
practices. Cases and controls were similar for 
most characteristics assessed (Table 2), although 
cases were more likely to have impaired smell 
recognition or to have a family history of PD, 
and were less likely to smoke.
To validate our approach to pesticide 
exposure assessment, we compared informa-
tion on use of four pesticides collected at 
enrollment in the AHS with information col-
lected for FAME. Despite an average lapse of 
9 years, agreement was good [DDT (dichlo-
rodiphenyltrichloroethane) 79%, 2,4-D (2,4-
dichlorophenoxyacetic acid) 84%, paraquat 
85%, rotenone 93%].
Ninety-eight percent of men and 44% of 
women had ever used pesticides. Information 
on 18 pesticides used by > 10 subjects is pre-
sented in Supplemental Material, Table 2 
Figure 1. Screening process of cases and controls. We identified 170 suspect cases and 644 potential con-
trols and screened 156 (92%) and 542 (84%) of these, respectively. We conducted study evaluations in 137 
(88%) of eligible suspect cases (including four initially identified as potential controls who self-reported PD 
at screening) and 383 (71%) of eligible potential controls. Suspect cases were evaluated in home visits or 
from medical records, matched controls in home visits. Final diagnoses in suspect cases were PD (115), 
essential tremor/other tremor disorder (12), no neurologic diagnosis (5), dystonia (2), multiple system 
atrophy (2), and atypical parkinsonism not fulfilling any diagnostic criterion (1). The latter three cases were 
subsequently termed “atypical parkinsonism.” 
Potential controls from
AHS available for FAME
n = 644
Self-reported PD
n = 4
Potential controls eligible
after telephone screen
n = 542
Controls evaluated
n = 383
all living
Controls with
pesticide data
n = 358
Suspect cases from AHS
available for FAME
n = 170
Suspect cases eligible
after telephone screen
n = 156
137 living, 19 dead
Suspect cases evaluated
n = 137
124 home visits, 13 proxy
interview and medical records
Control
n = 1
Conﬁrmed PD cases
n = 115
105 living, 10 dead
Conﬁrmed PD cases with
pesticide data
n = 110
101 living, 9 dead
Died, n = 2
Lost, n = 5
Unable, n = 4
Ineligible, n = 1
Refused, n = 87
Refused, n = 159
Lost, n = 3
Refused, n = 11
Ineligible, n = 4
Refused, n = 19
Not PD, n = 21Rotenone, paraquat, and Parkinson’s disease
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(doi:10.1289/ehp.1002839). Results from 
analyses in men were similar to those in 
men and women combined (Supplemental 
Material, Table 2). Information on pesticides 
linked to complex I inhibition or oxidative 
stress, regardless of the number of users, is 
presented in Table 3. Most of the pesticides 
in the oxidative stressor and mitochondrial 
inhibitor groups were used infrequently, lim-
iting individual analyses; but in general, use of 
these chemicals was more common in cases. 
Use of paraquat (OR = 2.5; 95% CI, 1.4–4.7) 
or any of the group of oxidative stressors (OR 
= 2.0; 95% CI, 1.2–3.6) was associated with 
PD (Table 3). Similarly, use of rotenone (OR 
= 2.5; 95% CI, 1.3–4.7) or any of the group 
of complex I inhibitors (OR = 1.7; 95% CI, 
1.0–2.8) was associated with PD (Table 3).
Associations between ever use of para-
quat or rotenone and PD were similar when 
exposures were truncated at 5, 10, or 15 
years before the diagnosis or reference date 
[paraquat: 5 years prior OR = 2.7 (95% 
CI, 1.4–4.9), 10 years OR = 2.9 (95% 
CI, 1.6–5.5), 15 years OR = 3.1 (95% CI, 
1.6–5.8); rotenone: 5 years prior OR = 2.3 
(95% CI, 1.2–4.4), 10 years OR = 2.4 (95% 
CI, 1.3–4.6), 15 years OR = 2.4 (95% CI, 
1.3–4.6]. Exposures to rotenone and paraquat 
were not correlated (r = 0.004), and ORs from 
a model that included both pesticides (para-
quat OR = 2.6; 95% CI, 1.4–4.9; rotenone 
OR = 2.9; 95% CI, 1.5–5.5) were compa-
rable with those from models without mutual 
adjustment (Table 3). For men who used para-
quat plus any dithiocarbamate (7 cases, 16 con-
trols), the OR compared with use of neither 
was 2.2 (95% CI, 0.79–5.9). Compared with 
never users, associations with PD were gener-
ally stronger among those who had used pes-
ticides for more than the median number of 
lifetime days than among those who had used 
pesticides for fewer than the median num-
ber of days [Supplemental Material, Table 3 
(doi:10.1289/ehp.1002839)].
Results from analyses stratified by race/
ethnicity, cigarette use, state, or duration of 
disease (in cases) were not appreciably differ-
ent between subgroups (data not shown). In 
an analysis restricted to 18 cases and 22 con-
trols (28 men and 12 women) with a first-de-
gree relative with PD, PD was not associated 
with ever exposure to rotenone (OR = 0.98) or 
paraquat (OR = 1.1). Adjustment for educa-
tion or overall pesticide use did not apprecia-
bly alter effect estimates, nor did exclusion of 
28 cases and 6 controls with proxy interviews 
or inclusion of 3 atypical parkinsonism cases.
We compared clinical features of cases 
who did or did not use paraquat or any oxi-
dative stressor, or rotenone or any complex I 
inhibitor (Table 4). PD was diagnosed at a 
younger age among those who used oxida-
tive stressors (mean age = 59 vs. 64 years, p = 
0.02). Although postural reflex impairment 
appeared to be less frequent in those using 
either paraquat or rotenone, these differences 
were not statistically significant. Clinical fea-
tures did not otherwise differ between groups. 
We were unable to determine whether expo-
sure to both paraquat and rotenone was asso-
ciated with unique clinical features because 
only five cases reported use of both pesticides 
(data not shown).
Discussion
The pathogenesis of PD is thought to involve 
several critical abnormalities, each of which 
can be the result of genetic or environmen-
tal factors. Chief among these abnormalities 
are dysfunction of the mitochondrial respi-
ratory chain, particularly complex I, and 
the production of reactive oxygen species 
(Henchcliffe and Beal 2008). To our knowl-
edge, we have performed the first analysis of 
pesticides classified by presumed mechanism, 
rather than by functional categories (e.g., her-
bicides) or chemical class (e.g., organochlo-
rines). We found significant associations of 
PD with use of groups of pesticides classified 
as complex I inhibitors or as oxidative stres-
sors, providing support in humans for find-
ings from decades of experimental work. In 
particular, PD was strongly associated with 
rotenone and paraquat, two individual pes-
ticides used extensively to model PD in the 
laboratory.
This study provides strong evidence of an 
association between rotenone use and PD in 
humans. PD developed 2.5 times as often in 
Table 2. Characteristics of subjects.
Characteristic Cases Controls
n 110 358
Age at FAME enrollment [years (mean ± SD)] 70 ± 8 69 ± 8
Men [n (%)] 80 (73) 265 (74)
Residence in Iowa (vs. North Carolina) [n (%)] 79 (72) 262 (73)
Non-Hispanic white (vs. other) [n (%)] 107 (97) 350 (98)
Pesticide applicator (vs. spouse) [n (%)] 80 (73) 267 (75)
Education > high school [n (%)] 49 (45) 178 (50)
PD in first-degree relative [n (%)] 18 (16) 22 (6)*
Smoked at least 100 cigarettes [n (%)] 31 (28) 141 (39)**
BSIT (mean score ± SD) 5.5 ± 2.8 8.8 ± 2.3#
CASI (mean score ± SD) 89.2 ± 8.5 93.1 ± 5.0#
Clinical features among casesa
Age at PD diagnosis [years (mean ± SD)] 61 ± 9  —
PD duration at FAME enrollment [years (median ± SD)] 7 ± 6 —
Resting tremor [n affected/n with data (%)] 100/108 (93) —
Bradykinesia [n affected/n with data (%)] 105/110 (95) —
Rigidity [n affected/n with data (%)] 106/107 (99) —
Postural reflex impairment [n affected/n with data (%)] 61/92 (66) —
Asymmetric onset [n affected/n with data (%)] 102/104 (98) —
Response to dopaminergic therapy (if prescribed) [n affected/n with data (%)] 95/98 (97) —
Abbreviations: BSIT, Brief Smell Identification Test; CASI, Cognitive Abilities Screening Instrument. 
aPercentages for clinical features are based on numbers of cases with features divided by the total number of cases 
with available data; cases with missing data for a feature are excluded. *p < 0.005 (Fisher’s exact test). **p < 0.05 
(Fisher’s exact test). #p < 0.001 (Wilcoxon rank-sum test).
Table 3. Association of PD with ever use of pesticides before diagnosis or reference date by mechanism.
Pesticide
Cases (n = 110) 
[n (%)]
Controls (n = 358) 
[n (%)] OR (95% CI) p-Value
Oxidative stressors
Paraquat 23 (24) 49 (14) 2.5 (1.4–4.7) 0.004
Permethrin 16 (16) 41 (12) 1.5 (0.77–2.9) 0.244
Carbon disulfide 2 (2) 3 (1) 2.6 (0.41–16) 0.313
Chloranil 1 (1) 3 (1) 1.6 (0.16–16) 0.706
Cyhalothrin 1 (1) 1 (0) 3.8 (0.22–64) 0.359
Dichlone 3 (3) 8 (2) 1.6 (0.40–6.2) 0.517
Mercury compounds 2 (2) 5 (1) 1.4 (0.26–7.5) 0.692
Pybuthrin 0 (0) 6 (2) NA
Any oxidative stressor  35 (40) 93 (28) 2.0 (1.2–3.6) 0.012
Mitochondrial complex I inhibitors
Benomyl 7 (7) 15 (4) 1.9 (0.70–5.0) 0.207
Carbendazim 1 (1) 2 (1) 2.2 (0.19–25) 0.529
Cyhalothrin 1 (1) 1 (0) 3.8 (0.22–64) 0.359
Permethrin 16 (16) 41 (12) 1.5 (0.77–2.9) 0.244
Pyridaben 0 (0) 1 (0) NA
Rotenone 19 (19) 32 (9) 2.5 (1.3–4.7) 0.005
Thiabendazole 3 (3) 12 (3) 0.8 (0.23–3.1) 0.778
Any complex I inhibitor 36 (38) 92 (27) 1.7 (1.0–2.8) 0.041
NA, not available. Analyses used logistic regression adjusted for reference age tertile, sex, state, and cigarette smoking.Tanner et al.
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those who reported use of rotenone compared 
with nonusers, and an association of similar 
magnitude was observed even when exposure 
was truncated up to 15 years before PD diag-
nosis. In our prior analysis of self-reported 
PD in the AHS, information on rotenone was 
available for a small subgroup, and nonsignifi-
cant association with PD (OR = 1.7; 95% CI, 
0.6–4.7) was observed (Kamel et al. 2007), 
whereas in a multicenter, clinic-based case–
control study distinct from the AHS, only two 
individuals were exposed and no association 
was observed (Tanner et al. 2009). In the only 
other report of rotenone-like compounds and 
PD, use of organic pesticides such as rote-
none in the previous year was determined for 
PD clinic attendees, who reported current use 
more often than did cases with other neu-
rologic diseases (Dhillon et al. 2008). This 
information cannot be used to assess etiology, 
because the study evaluated associations with 
rotenone use that occurred after PD had been 
diagnosed. In contrast, in the present pop-
ulation-based study, we evaluated rotenone 
use before PD diagnosis in cases and during 
a comparable time period in neurologically 
healthy controls.
Rotenone is a plausible cause of PD 
because of its mechanism of action. Like 
1-methyl-4-phenyl-1,2,3,6-tetrahydropyri-
dine (MPTP), a toxicant known to cause 
parkinsonism in humans, rotenone directly 
inhibits mitochondrial complex I (Langston 
et al. 1983; Sherer et al. 2007). In experi-
mental models, both MPTP and rotenone 
cause selective injury of dopaminergic neu-
rons in the substantia nigra, a key pathologi-
cal feature of PD (Greenamyre et al. 1999; 
Langston et al. 1984). Because rotenone is 
believed to have a relatively short environ-
mental half-life and limited bioavailability, a 
relationship to human disease has been ques-
tioned (Hatcher et al. 2008; Li et al. 2005). 
However, recent work in rodent models indi-
cated that a temporally limited exposure to 
rotenone later caused progressive functional 
and pathologic changes in the enteric nervous 
system of rodents, mimicking changes found 
in human PD; as in PD, these enteric ner-
vous system changes preceded central nervous 
system pathology (Abbott et al. 2001; Braak 
et al. 2006; Drolet et al. 2009; Greene et al. 
2009; Pan-Montojo et al. 2010). Chronic 
rotenone exposure in the laboratory has been 
reported to have additional effects associated 
with PD pathogenesis, including ones similar 
to changes observed in monogenic forms of 
PD (Henchcliffe and Beal 2008). Rotenone 
toxicity, therefore, provides a conceptual 
bridge, suggesting shared mechanisms for 
both sporadic and inherited forms of PD.
Although we report here findings for agri-
cultural use of rotenone, the ubiquitous use 
of rotenone in both work and home settings 
that occurred until recently suggests that many 
people may have been exposed. Humans have 
used rotenone-containing plants as pesticides 
for centuries (Cabras et al. 2002). Because 
rotenone is plant derived, it has been con-
sidered an organic pesticide and was com-
monly used as a household insecticide in 
home gardening and agriculture, and to kill 
fish. For example, the California Department 
of Pesticide Regulation (2007) reported that 
almost 15,000 pounds of rotenone were used 
in 2007, not including home use. Rotenone 
was withdrawn from use in the European 
Union in 2007 (Schapira 2010), after which 
time most uses were voluntarily cancelled in 
the United States (U.S. EPA 2007). Other 
agents associated with mitochondrial com-
plex I inhibition remain in common use. For 
example, permethrin is used in nonagricultural 
settings as an insect repellant, including use 
of permethrin-impregnated fabric for military 
uniforms and recreational clothing (Armed 
Forces Pest Management Board 2010).
Our study also extends prior research 
on paraquat. Experimentally, paraquat pro-
duces subcellular changes associated with PD, 
including increased production of reactive 
oxygen species, alpha-synuclein aggregation, 
and selective nigral injury (Dinis-Oliveira et al. 
2006; Kuter et al. 2010; McCormack et al. 
2002). Previously, we found an association 
between paraquat use and PD in prevalent but 
not incident self-reported cases in the AHS 
(Kamel et al. 2007) and a nonsignificant asso-
ciation between PD and occupational para-
quat use in a multicenter case–control study 
(Tanner et al. 2009). Cumulative use was not 
assessed in either study. Only a few other stud-
ies have assessed associations between PD and 
paraquat use (Table 1). A study of 120 cases 
and 240 controls conducted in Taiwan (Liou 
et al. 1997) reported an OR of 3.22 (95% 
CI, 2.41–4.31) for PD in paraquat users com-
pared with nonusers. Cumulative exposure 
was associated with greater risk, but paraquat 
use in the Taiwanese study was highly cor-
related with use of other herbicides. Although 
the inconsistency of findings in human popu-
lations has been used as a basis for suggesting 
that paraquat is not associated with PD (Li 
et al. 2005; Miller 2007), an alternative expla-
nation is that few studies have had adequate 
size and sufficiently detailed exposure informa-
tion to allow the association to be observed. 
Our findings, considered together with earlier 
results, suggest that paraquat use plays a role 
in human PD. Because paraquat remains one 
of the most widely used herbicides worldwide 
(Frabotta 2009), this finding potentially has 
great public health significance.
Parkinsonism in humans due to high-dose 
exposure to toxicants such as carbon mon-
oxide or manganese has characteristic clini-
cal features including less prominent tremor, 
more prominent postural instability, symmet-
ric distribution of signs, and poor response to 
dopaminergic therapy (Tanner 1992). We did 
not observe such features in our cases. Cases 
who did or did not use rotenone, paraquat, or 
groups of pesticides with similar mechanisms 
were generally similar, suggesting that PD asso-
ciated with these agents is clinically typical and 
indirectly supporting a role for pesticide expo-
sure in the etiology of typical PD. We did note 
an earlier age at diagnosis in users of oxidative 
stressors and a suggestion of this in paraquat 
users specifically. Early age at onset is also a 
characteristic of genetic parkinsonism in which 
oxidative stress is a presumed pathophysiologic 
mechanism (alpha-synuclein, PINK-1, DJ-1, 
and PARKIN mutations) (Henchcliffe and Beal 
2008; Klein et al. 2009).
In FAME, pesticide exposure was not 
associated with PD in individuals with a fam-
ily history, although numbers were small. 
Interestingly, Hancock et al. (2008) similarly 
Table 4. Clinical features of PD cases by use of paraquat or rotenone or mechanistic group.
Paraquat Any oxidative stressor Rotenone Any complex I inhibitor
Characteristic 
Exposed 
(n = 23)
Not exposed 
(n = 74)
Exposed 
(n = 35)
Not exposed 
(n = 53)
Exposed 
(n = 19)
Not exposed 
(n = 82)
Exposed 
(n = 36)
Not exposed 
(n = 59)
Age at PD diagnosis [years (mean ± SD)] 59 ± 8 62 ± 9 59 ± 8 64 ± 9* 65 ± 11 61 ± 8 61 ± 11 62 ± 8
PD duration [years (mean ± SD)] 8.6 ± 6 8.4 ± 6 8.2 ± 6 7.6 ± 5 7.7 ± 7 8.7 ± 5 8.2 ± 6 8.5 ± 5
Clinical features [n with feature/n with data available (%)]
Resting tremor 21/22 (95) 66/73 (90) 31/34 (91) 49/53 (92) 17/18 (94) 75/81 (93) 32/35 (91) 54/58 (93)
Bradykinesia 22/23 (96) 70/74 (95) 33/35 (94) 50/53 (94) 17/19 (89) 79/82 (96) 34/36 (94) 56/59 (95)
Rigidity 23/23 (100) 72/73 (99) 33/34 (97) 50/53 (94) 18/19 (95) 80/80 (100) 34/35 (97) 58/58 (100)
Postural reflex impairment 10/21 (48) 43/62 (69) 18/31 (58) 29/43 (67) 7/15 (47) 48/69 (70) 16/28 (57) 37/52 (71)
Asymmetric onset 23/23 (100) 69/71 (97) 35/35 (100) 49/51 (96) 18/18 (100) 77/79 (97) 35/35 (100) 54/56 (96)
Response to dopaminergic therapy (if prescribed) 21/21 (100) 63/65 (97) 30/30 (100) 46/48 (96) 14/15 (93) 73/74 (99) 30/31 (97) 53/54 (98)
*Difference between exposed versus not exposed p = 0.02.Rotenone, paraquat, and Parkinson’s disease
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found pesticide exposure to be associated with 
PD risk only in those without an affected 
first-degree relative. 
Our study has some limitations. First, 
because most participants were exposed to 
many pesticides, we cannot confidently exclude 
effects of agents other than those studied or rule 
out the possibility that our results are attrib-
utable to combined exposures. However, the 
associations that we observed remained after 
adjustment for overall pesticide use, and esti-
mated effects of rotenone and paraquat were 
comparable after mutual adjustment. Future 
investigations of combinations of pesticides and 
of other mechanistic groups will be important. 
Second, we could not use laboratory measures 
of pesticides or their metabolites to estimate 
exposure. Such measures are not available for 
many of the pesticides we studied, and when 
available, they are poor predictors of past or 
long-term use. Thus, although we recognize 
that retrospective exposure assessment has limi-
tations, it is often the best approach for study-
ing lifelong exposure in an adult population 
in connection with a rare disease. Third, we 
included prevalent cases already diagnosed but 
still living at enrollment in the AHS; therefore, 
survivor bias is possible. However, our results 
were similar when only those with shorter dis-
ease duration were analyzed. Additionally, we 
were able to investigate only persons willing to 
participate. Thus, PD cases or controls in this 
study may not have been fully representative 
of the entire population. However, participa-
tion was good, partially allaying this concern. 
Finally, we selected pesticides presumed to act 
through specific toxic mechanisms, but for most 
pesticides there is very little information regard-
ing toxic effects in humans, as most studies are 
directed toward effects on plant or animal pests. 
It is likely that we have misclassified some pesti-
cides with regard to mechanism. However, the 
likely effect of any misclassification would be to 
attenuate an association with pesticides grouped 
according to a common mechanism.
Strengths include the size of the study; 
the focus on an agricultural cohort with many 
exposed individuals and wide variability in 
exposure; the quality of diagnosis, which was 
based on in-person assessment and agreement 
of movement disorders experts; and the com-
pleteness and reliability of the pesticide expo-
sure information. An additional strength is 
the nested case–control design with an inter-
nal control group who had similar exposure 
opportunities as the cases and similar demo-
graphic and lifestyle characteristics, reducing 
the likelihood of bias or confounding. Use 
of pesticides in general was ubiquitous, of 
course, in applicators and relatively common 
among their spouses, and all participants may 
have had additional passive pesticide exposure. 
However, these features would all be likely to 
lower the chance of identifying any effect.
Our study helps connect the dots between 
basic research and human populations. 
Rotenone and paraquat have been linked 
experimentally to pathophysiological mecha-
nisms implicated in human PD. Groups of 
pesticides linked to the mechanisms of mito-
chondrial dysfunction or oxidative stress were 
also associated with PD in our study, thus 
extending experimental work to provide strong 
evidence that these mechanisms play a role 
in PD in humans. Importantly, the poten-
tial for exposure to many of these pesticides, 
including rotenone and paraquat, extends well 
beyond the occupational setting. Many per-
sons with nonoccupational pesticide exposures 
may be unaware of the presence of pesticides 
in their environments (Centers for Disease 
Control and Prevention 2009). The potential 
for exposure to other toxicants with similar 
mechanisms is even greater. To continue the 
interplay between human and experimental 
studies, future mechanistic studies of these pes-
ticides should model exposure conditions simi-
lar to those occurring in humans, including 
chronic low-dose exposure, exposure to mul-
tiple agents, and assessment of gene–exposure 
interactions. Such work could provide new 
insights into the pathogenesis and ultimately 
the prevention of PD.
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